key: cord-0991847-jx7cqu7t
authors: Zahan, MN; Habibi, H.; Pencil, A.; Abdul-Ghafar, J.; Ahmadi, SA; Juyena, NS; Rahman, MT; Parvej, MS
title: Diagnosis Of Covid-19 In Symptomatic Patients: An Updated Review
date: 2021-07-13
journal: Vacunas
DOI: 10.1016/j.vacun.2021.06.002
sha: 662df4e006748d3e64506b741a1baba602e2a71e
doc_id: 991847
cord_uid: jx7cqu7t

A group of pneumonia patients was detected in Hubei Province, in China in December 2019. The etiology of the disease was unknown. Later, the researchers diagnosed the novel Coronavirus as the causal agent of this respiratory disease. On February 12th 2020, the World Health Organization (WHO) officially named this disease Coronavirus disease 2019 (COVID-19). Consequently, the disease spread globally and became a pandemic. As there is no specific treatment for the symptomatic patients and several vaccines are approved by WHO, the efficacy and effectiveness of these vaccines are not fully understood yet and the availability of these vaccines are very limited. In addition, new variants and mutants of SARS-CoV-2 are thought to be able to evade the immune system of the host. So, diagnosis and isolation of infected individuals is advised. Currently, real-time reverse transcription-polymerase chain reaction (RT-PCR) is considered the gold standard method to detect novel Coronavirus, however, there are few limitations associated with RT-PCR such as false-negative results. This demanded another diagnostic tool to detect and isolate COVID-19 early and accurately. Chest computed tomography (CT) became another option to diagnose COVID-19 patients accurately (about 98% sensitivity). However, it did not apply to the asymptomatic carriers and sometimes the results were misinterpreted as from other groups of Coronavirus infection. The combination of RT-PCR and chest CT might be the best option in detecting novel Coronavirus infection early and accurately thereby allowing adaptation of measures for the prevention and control of the COVID-19.

3 En diciembre de 2019 se detectó un grupo de pacientes con neumonía en la provincia de Hubei, China, desconociéndose la etiología de la enfermedad. Posteriormente, los investigadores señalaron al nuevo coronavirus como agente causal de esta enfermedad respiratoria. El 12 de febrero de 2020, la Organización Mundial de la Salud (OMS) la designó oficialmente como enfermedad por coronavirus de 2019 . A continuación, dicha enfermedad se propagó a nivel global y se convirtió en una pandemia. No existe tratamiento específico para los pacientes sintomáticos, y la OMS ha aprobado diversas vacunas. Sin embargo, la eficacia y efectividad de las mismas no se comprende plenamente aún, siendo muy limitada su disponibilidad. Además, se piensa que las diferentes variantes y mutaciones de SARS-CoV-2 son capaces de evadir el sistema inmune del huésped. Por tanto, se recomienda el diagnóstico y aislamiento de las personas infectadas. Actualmente se considera la reacción en cadena de la polimerasa con transcriptasa inversa (RT-PCR) a tiempo real el método de referencia para detectar el nuevo coronavirus. Sin embargo, existen algunas limitaciones asociadas a RT-PCR tales como los resultados falso-negativos. En consecuencia, ello ha demandado otra herramienta diagnóstica para detectar y aislar la COVID-19 de manera temprana y precisa. La tomografía computarizada (TC) de tórax se ha convertido en otra opción para diagnosticar de manera precisa a los pacientes con COVID-19 (cerca del 98% de sensibilidad). Sin embargo no se aplica a los portadores asintomáticos y a veces se han malinterpretado los resultados como en el caso de otros grupos de infección por coronavirus. La combinación de RT-PCR y TC de tórax podría ser la mejor opción para detectar la nueva infección por coronavirus de manera temprana y precisa, permitiendo por tanto la adaptación de las medidas para la prevención y control de la COVID-19. Real-time reverse transcription polymerase-chain-reaction (RT-PCR) is currently being considered the gold standard method globally for accurate diagnosis of COVID-19 either in symptomatic patients or asymptomatic carriers. In addition to this, some scientists suggest chest computed tomography (Chest-CT) as an alternative tool for the diagnosis of COVID-19 effectively and accurately in symptomatic patients 22 . This review focuses on various aspects of these two diagnostic methods including their suitability to detect COVID-19.

RT-PCR is a widely utilized technique in diagnostic virology. During a public health emergency, a competent virology laboratory can rely on this molecular technique to ascertain new diagnostic tests before new reliable assays are offered. RT-PCR is the diagnostic technique used worldwide to detect SARS-CoV-2 and this test is approved by WHO and the Center for disease control and prevention (CDC) in the diagnosis of COVID-19 23 . Coronaviruses express several molecular targets that can be identified by 25 . In this molecular test, samples are usually taken via the nasopharyngeal (the part of the throat behind the nose) together with the saliva. Based on the previously reviewed articles the sputum test is more reliable, but the sputum is not available if the patient does not have a productive cough. Therefore, the saliva-based SARS-CoV-2 shows promising results. It also allows self-sample collection 26 

Although RT-PCR is considered the standard test to diagnose COVID-19 worldwide, two different groups of scientists from China reported 3% and 30% false-negative results after the RT-PCR test 28, 29 . One research group from China found a RT-PCR positive result the third time after a patient's results showed false-negative results in two consecutive tests. 30 However, the main reasons for false-negative results in RT-PCR might include the use of low-sensitivity primers, testing kits, and RT-PCR technology. Sample source, sample collection by unskilled personnel, and sampling mistiming (low virus load in patients during the sampling time) also contribute to false-negative results 28 .

9 Chest CT is the imaging technology based on X-ray and computer technology to visualize the organs and structures in the chest. This is more reliable than a regular Xray to identify the abnormalities in the chest organs. During the CT scan, an X-ray beam transfers through the patient's chest, and takes many high-resolution medical images of the lungs and other organs by radiation detectors, and displays them on a monitor 34 .

Chest CT has been using in clinical practices to diagnose diseases and disorders since 1972 35 . This method is quite rapid than molecular tests and it is a vital diagnostic tool to detect viral pneumonia in COVID-19 suspected patients 36 

CT images of SARS-CoV-2 infected patients had similarities with SARS-CoV-1.

Although a few differences were noticed, these two pathogens of the Coronavirus group revealed mainly ground-glass opacities, with consolidation that was seen sporadically 43 Furthermore, Caruso and colleagues (2020) reported that chest CT had a low specificity rate of (56%) and high sensitivity (97%) as a diagnostic tool among Italian COVID-19 patients 39 . Also, another research group from China stated that chest CT had high specificity (96%) when done by well-trained radiologists in clinical settings 48 .

Moreover, Bernheim and colleagues reported that chest CT could not detect COVID-19 in suspected patients after the onset of symptoms (0-2 days). It is not a reliable method when used independently to test/detect SARS-CoV-2 infection in clinical settings 37 .

SARS CoV-2 cannot be detected appropriately by chest CT alone in asymptomatic patients (Table-1) . Besides, the results of chest CT might be misinterpreted as SARS CoV-1or other respiratory viral infection and its specificity rate is not satisfactory 12 compared to RT-PCR (Table-1) . Furthermore, the false-negative results in chest CT can be minimized by well-trained radiologists 36 . Skilled radiologists can minimize the harmful health effects of X-ray radiation by reducing the dose of the radiation without affecting the image quality 52 . Ultimately, chest CT is useful as a diagnostic tool that may compensate for initial false-negative RT-PCR results in COVID-19 suspected patients.

RT-PCR-based molecular diagnosis of Covid-19 has been done globally since the genetic sequence of SARS-CoV-2 was made available. The molecular test requires robust laboratory facilities and skilled laboratory personnel. The results of RT-PCR should be available within 2-4 hours of sample collection but some countries experience delays of up to seven days 53 . This delay may facilitate the transmission of the virus to a wide range of new hosts because the suspected patients will resume their daily activities until they receive the test results. This leads to an increase in the number of new patients and the pandemic becomes uncontrollable. An alternative tool/assay that can alleviate the limitations of RT-PCR is the Rapid antigen test. It can detect the SARS-CoV-2 virus within 15-20 minutes. It is cost-effective, easily applicable outside the laboratory facilities, no need for skilled personnel, and applies to many patients. Although the rapid antigen test kits are highly specific, their sensitivity is not as high as other molecular tests 54 . WHO explained that although the sensitivity of the antigen test is lower than the molecular test, it is suitable due to its rapid performance, low cost, and applies to symptomatic patients with high viral load and having increased chances of transmitting the pathogen to others 55 56, 57 . Additionally, WHO recommended that the Rapid antigen test kit should have the minimum 80% sensitivity and 97% specificity 55 . Another advantage of using antigen test is its ability to detect large numbers of asymptomatic carriers who frequently moves from one region to another, for example in the airport, school, industry, workplace, and mass gatherings. The antigen test is readily applicable in places where molecular tests are not available to diagnose and isolate symptomatic patients or suspected asymptomatic carriers. This test can also be a preliminary screening test before RT-PCR and Chest CT within large groups of patients. Unlike molecular tests, saliva samples are not preferred in antigen tests due to low viral load, instead, nasopharyngeal swabs are suggested by researchers because some saliva samples whose viral load was not detected by the antigen test showed positive results in subsequent molecular tests 58 . Similarly, rapid antigen test should not be used singlehandedly to detect COVID-19 and it is not a replacement for molecular tests since it is appropriate only when the patient has a high viral load.

A rapid antigen test is mostly applicable within 7 days of the onset of the infection when the viral load is high enough to be detected by the test. However, if the patient comes to the laboratory or hospital after 7 days of the onset of the infection when viral load is reduced to a level that is undetectable by the Rapid antigen test, the best option is to perform a combination of rapid antibody tests and molecular test 59, 60 . The antibody concentration of the infected patients becomes detectable after the first week of the onset of the symptoms, and a combination of antibody tests with molecular tests is suggested in this period 61, 62 . Serological testing alone is less effective in diagnostic facilities to control a pandemic because 44% of SARS-CoV-2 virus transmission happens during the pre-symptomatic stage 63 before the antibodies become detectable.

If the molecular test or CT scan is not available or the demands for confirming the COVID-19 patients exceed the capacity of RT-PCR, rapid antigen tests and the serological assay can be convenient. This combination of techniques should have high sensitivity and will be useful in the rapid detection and isolation of COVID-19 patients.

Rapid accurate diagnosis is crucial for providing effective treatment, prevention, and control of any disease. So far, RT-PCR is the gold standard method being used worldwide to diagnose COVID-19 among symptomatic patients and/or asymptomatic suspected carriers. On the other hand, chest CT, rapid antigen test, and serological assays could be other options besides RT-PCR to increase the accuracy of diagnosis in symptomatic patients. Simultaneously, chest CT can be a second option and readily applicable after RT-PCR for clinically suspected SARS-CoV-2 infections, especially when the initial RT-PCR result is negative. A combination of rapid antigen tests with serological assays is helpful to screen many patients in clinical settings when the availability of RT-PCR is limited. We recommend a combination of RT-PCR and chest CT as the best method to detect COVID-19 accurately among hospitalized symptomatic patients.

None to declare Author Contribution 

Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia

A Novel Coronavirus from Patients with Pneumonia in China

Coronavirus pathogenesis

Genetic Recombination, and Pathogenesis of Coronaviruses

Origin and evolution of pathogenic coronaviruses

Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in COVID-19

Risk for Transportation of Coronavirus Disease from Wuhan to Other Cities in China

Covid-19: Moderna vaccine is nearly 95% effective, trial involving high risk and elderly people shows

Covid-19: Pfizer and BioNTech submit vaccine for US authorisation

Covid-19: Pfizer vaccine efficacy was 52% after first dose and 95% after second dose, paper shows

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. The Lancet

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

The Spike D614G mutation increases SARS-CoV-2 infection of multiple human cell types. bioRxiv

D614G mutation of SARS-CoV-2 spike protein enhances viral infectivity. bioRxiv

Spike mutation D614G alters SARS-CoV-2 fitness

On the origin and continuing evolution of SARS-CoV-2

UK identifies new coronavirus variant; London on toughest curbs | Coronavirus pandemic News | Al Jazeera

Correlation of Chest CT and RT-PCR Testing for Coronavirus Disease

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Improved Molecular Diagnosis of COVID-19 by the Novel, Highly Sensitive and Specific COVID-19-RdRp/Hel Real-Time Reverse Transcription-PCR Assay Validated In Vitro and with Clinical Specimens

Laboratory Diagnosis of COVID-19: Current Issues and Challenges

New COVID-19 saliva-based test: How good is it compared with the current nasopharyngeal or throat swab test?

Saliva is a reliable, non-invasive specimen for SARS-CoV-2 detection

Sensitivity of chest CT for COVID-19: comparison to RT-PCR

Chest CT for typical 2019-nCoV pneumonia: relationship to negative RT-PCR testing

Use of chest CT in combination with negative RT-PCR assay for the 2019 novel coronavirus but high clinical suspicion

Negative nasopharyngeal and oropharyngeal swabs do not rule out COVID-19

Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction-Based SARS-CoV-2 Tests by Time Since Exposure

The Potential Transmission of SARS-CoV-2 from Patients with Negative RT-PCR Swab Tests to Others: Two Related Clusters of COVID-19 Outbreak

Validation of the British Society of Thoracic Imaging guidelines for COVID-19 chest radiograph reporting

Trends in the use of radiology with inpatients: what has changed in a decade?

Low-Dose Chest CT for the Diagnosis of COVID-19-A Systematic

Chest CT findings in coronavirus disease-19 (COVID-19): relationship to duration of infection

Time Course of Lung Changes at Chest CT during Recovery from Coronavirus Disease 2019 (COVID-19)

Chest CT Features of COVID-19 in

Chest CT Findings in Patients With Coronavirus Disease 2019 and Its Relationship With Clinical Features

Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study

Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies

Imaging Profile of the COVID-19 Infection: Radiologic Findings and Literature Review

Coronavirus disease 2019 (COVID-19): role of chest CT in diagnosis and management

CT imaging features of 2019 novel coronavirus (2019-nCoV)

Coronavirus disease 2019 (COVID-19): chest CT characteristics benefit to early disease recognition and patient classification-a single center experience

Chest CT Findings in Cases from the Cruise Ship "Diamond Princess

Diagnostic performance between CT and initial real-time RT-PCR for clinically suspected 2019 coronavirus disease (COVID-19) patients outside Wuhan, China

Diagnosis of the Coronavirus disease (COVID-19): rRT-PCR or CT?

CT in relation to RT-PCR in diagnosing COVID-19 in The Netherlands: A prospective study

Cost-Utility Analysis for Chest CT versus RT-PCR for COVID-19 Detection

Simulated dose reduction in conventional chest CT: validation study

COVID-19 Test Result Turnaround Time for Residents and Staff in US Nursing Homes

Scaling up COVID-19 rapid antigen tests: promises and challenges

Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays

Emergency use listing procedure for In Vitro diagnostics

Comparison of Rapid Antigen Tests for COVID-19

Serology testing in the COVID-19 pandemic response

Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease

Performance of Dengue Diagnostic Tests in a Single-Specimen Diagnostic Algorithm

Reimagining the Future of the Diagnosis of Viral Infections

Temporal dynamics in viral shedding and transmissibility of COVID-19